Treatment of newly diagnosed epilepsies: The shortcomings of SANAD

Developmental Medicine and Child Neurology

Volumn 50, Issue 4, 2008, Pages 247-

  Ferrie, Colin D ^a   Grünewald, Richard A ^a   Livingston, John H ^a   Panayiotopoulos, Chrysostomos P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; VALPROIC ACID;

CLINICAL TRIAL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG PREFERENCE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; EPILEPSY; FOCAL EPILEPSY; GRAND MAL SEIZURE; HUMAN; NEUROIMAGING; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ANTICONVULSANTS; CARBAMAZEPINE; CHILD; EPILEPSY; FOLLOW-UP STUDIES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TRIAZINES; VALPROIC ACID;

EID: 41149133996     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2008.00247.x     Document Type: Note

References (5)

1. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: An unblinded randomised controlled trial. Lancet 2007; 369: 1000-15.
2. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: An unblinded randomised controlled trial. Lancet 2007; 369: 1016-26.
3. Marson AG, Appleton R, Baker GA, et al. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. Health Technol Assess 2007; 11: 1-134.
4. Berg AT. Hypotheses, tests, methods, and innovation: The balancing act in research. Epilepsia 2007; 48: 2204-16.
5. King MA, Newton MR, Jackson GD, Berkovic SF. Epileptology of the first-seizure presentation: A clinical, electroencephalographic, and magnetic imaging study of 300 consecutive patients. Lancet 1998; 352: 1007-11.